International Patent: TREATMENT OF MUSCLE DISORDER WITH FOLLICULIN INTERACTING PROTEIN 1 (FNIP1) INHIBITORS AND/OR FOLLICULIN (FLCN) INHIBITORS

GENEVA, Aug. 31 -- REGENERON PHARMACEUTICALS, INC. filed a patent application (US2025/016736) for “TREATMENT OF MUSCLE DISORDER WITH FOLLICULIN INTERACTING PROTEIN 1 (FNIP1) INHIBITORS AND/OR FOLLICULIN (FLCN) INHIBITORS”. With publication no. WO/2026/177719, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C12N 15/113

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....